Summary:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia.
Qualified Participants Must:
• Be 13 to 65 years of age
• have a confirmed diagnosis of schizophrenia
• be clinically stable
• be eligible for risperidone treatment
Qualified Participants May Receive:
Transportation and a stipend